Removing the bone brake

Georg Schett; Aline Bozec

doi:10.1016/j.cmet.2014.08.009

Removing the bone brake

Cell Metab. 2014 Sep 2;20(3):394-5. doi: 10.1016/j.cmet.2014.08.009.

Authors

Georg Schett¹, Aline Bozec²

Affiliations

¹ Department of Internal Medicine 3 and Institute of Clinical Immunology, University of Erlangen-Nuremberg, 91054 Erlangen, Germany. Electronic address: georg.schett@uk-erlangen.de.
² Department of Internal Medicine 3 and Institute of Clinical Immunology, University of Erlangen-Nuremberg, 91054 Erlangen, Germany.

PMID: 25185946
DOI: 10.1016/j.cmet.2014.08.009

Abstract

Osteoporosis results from an imbalance between bone resorption and bone formation. While bone resorption inhibitors are widely used to treat osteoporosis, stimulating bone formation is more challenging. Recently, McClung et al. (2014) found that neutralization of sclerostin, a potent inhibitor of bone formation, effectively increased bone mass in postmenopausal women.

Publication types

Comment

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Bone Density / drug effects*
Bone Density Conservation Agents / administration & dosage*
Bone Remodeling / drug effects*
Female
Humans
Osteoporosis, Postmenopausal / drug therapy*

Substances

Antibodies, Monoclonal
Bone Density Conservation Agents